That was probably the justification for a high valuation. Also explains the recent pharma pivot.
Their existing data can't really be used for personalized medicine. If they want to pursue that market they'll need different testing protocols and additional regulatory approvals.
regulatory approval is easy to get with the right kind of lobbying.
i would say assays are useful for personal medicine. they get about 6m variants.